Research suggests that GLP-1 receptor agonists may reduce the risk of certain obesity-related cancers, with some studies indicating a potential decrease in metastatic progression and improved survival outcomes. However, the findings are not uniform, with one report suggesting that these medications may have little effect on obesity-related cancer risk. The specific types of cancer that may be affected, such as pancreatic, colorectal, and breast cancer, are also being explored.